Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Other financing activities (2019 - 2021)

Harmony Biosciences Holdings (HRMY) has disclosed Other financing activities for 3 consecutive years, with $8.9 million as the latest value for Q4 2021.

  • Quarterly Other financing activities rose 172.6% to $8.9 million in Q4 2021 from the year-ago period, while the trailing twelve-month figure was -$3.3 million through Dec 2023, changed N/A year-over-year, with the annual reading at $3.0 million for FY2023, N/A changed from the prior year.
  • Other financing activities hit $8.9 million in Q4 2021 for Harmony Biosciences Holdings, up from -$12.2 million in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $8.9 million in Q4 2021 to a low of -$12.2 million in Q4 2020.
  • Historically, Other financing activities has averaged $671000.0 across 3 years, with a median of $875000.0 in 2019.
  • Biggest five-year swings in Other financing activities: plummeted 1493.49% in 2020 and later skyrocketed 172.6% in 2021.
  • Year by year, Other financing activities stood at $875000.0 in 2019, then tumbled by 1493.49% to -$12.2 million in 2020, then surged by 172.6% to $8.9 million in 2021.
  • Business Quant data shows Other financing activities for HRMY at $8.9 million in Q4 2021, -$12.2 million in Q4 2020, and $17000.0 in Q3 2020.